Drugs / nesvacumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01997164 | Nov 2014 → Oct 2015 | diabetic macular edema, wet macular degeneration | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01688960 | Oct 2012 → Nov 2014 | cancer | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01271972 | Jan 2011 → Sep 2014 | cancer | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02712008 | Mar 2016 → Jul 2017 | diabetic macular edema | Regeneron Pharmaceuticals | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-11-27 | Regeneron Pharmaceuticals | Results Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to EYLEA® (aflibercept) Injection did not provide sufficient differentiation to warrant Phase 3 development. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-27 | Regeneron Pharmaceuticals | Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program regeneron.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nesvacumab | “Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)” NCT02712008 ↗ |
| Known as | REGN910 | “Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)” NCT02712008 ↗ |
| Known as | SAR307746 | “nesvacumab (REGN910/ SAR307746)” NCT01688960 ↗1“nesvacumab (REGN910/ SAR307746)” NCT01271972 ↗ |
| Action | Inhibit | “Angiopoietin-2 inhibitor” CHEMBL2108678 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108678 ↗ |
| Route | Intravenous | “administered IV every 2 weeks” NCT01271972 ↗ |
| Target | ANGPT2 | “Angiopoietin-2 inhibitor” CHEMBL2108678 ↗ |